Adam Shaywitz, MD, PhD is the Chief Medical Officer at BridgeBio Gene Therapy (BBGT), which is part of the larger BridgeBio Pharma portfolio focused on finding and developing novel treatment approaches for genetically driven disease. BBGT is developing gene therapy treatments for a range of monogenic rare diseases including clinical-stage programs for Canavan disease and congenital adrenal hyperplasia. Prior to joining BridgeBio Adam worked at BioMarin Pharmaceutical where he led programs aimed at treating a broad range of rare diseases including Sanfilippo Syndrome (MPS III), achondroplasia, endocrinologic disorders, Morquio A syndrome and other lysosomal storage disorders. Before joining BioMarin Adam spent four years at Amgen in their early clinical development group, focused on advancing promising diabetes and metabolism agents into the clinic. He received his M.D. and Ph.D. degrees from Harvard Medical School, did his internal medicine training at MGH and subsequently went on to pursue a fellowship in endocrinology, diabetes and metabolism at Beth Israel-Deaconess Medical Center and the Joslin Diabetes Center. Adam currently serves on the Board of Directors at Cure Sanfilippo Foundation.